Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
about
Nanostructures for the Inhibition of Viral InfectionsElectrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIVNanoparticle-based drug delivery to the vagina: a review.Nanoparticulate drug delivery platforms for advancing bone infection therapies.Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Combination antiretroviral therapy and cell-cell spread of wild-type and drug-resistant human immunodeficiency virus-1.Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maravirocNonlinear effects of nanoparticles: biological variability from hormetic doses, small particle sizes, and dynamic adaptive interactions.The role of nanotechnology in the treatment of viral infections.Design and in vitro evaluation of tenofovir-loaded vaginal gels for the prevention of HIV infections.Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.Nanoparticle-releasing nanofiber composites for enhanced in vivo vaginal retention.Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.Caffeic Acid Phenethyl Ester Loaded PLGA Nanoparticles: Effect of Various Process Parameters on Reaction Yield, Encapsulation Efficiency, and Particle Size
P2860
Q26801513-67ADCB4D-8E94-45BB-8C22-B59A09D63296Q34058160-810C93BE-C84F-4E18-8C01-3B3E23514AC4Q34079533-8A3CFDA0-D2D5-4C13-A10A-11B1BDF1B7B5Q35373671-43AE218A-7FA0-49E9-9121-F9C9288ABEB0Q35947035-F753E284-0410-4252-A077-8656B7EBBF36Q36934918-A5F5FD1C-6B67-4458-8807-D3B629A6A604Q38718627-7268E3F5-9FA9-4A3A-8D36-4B2C47A752CEQ38781199-5FB38CDB-5D3C-4480-B749-3A003C05EE2CQ40000942-55C5F219-4B80-461B-A505-56599C5D0B4EQ40106774-2DCDB61C-90C5-4E3C-A47A-334D5EF4D6DCQ40201612-30417BF9-B9AD-412F-BD16-AF2A664B48E2Q41339468-8BD455AD-2EAD-4E61-B762-731623E95A65Q46448056-6FA53594-8780-4FD6-B3DE-BAB26AF9D6C5Q47930607-F26E30A0-9FC1-4E15-AA89-CDD1F6C4D2C2Q55338133-619CB11C-3665-4E4A-86BC-71DC57BF4FEFQ59113344-4264CE26-17E0-4CC1-A950-A07EBD277C5F
P2860
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
@ast
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
@en
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
@nl
type
label
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
@ast
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
@en
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
@nl
prefLabel
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
@ast
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
@en
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
@nl
P2093
P2860
P1433
P1476
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis
@en
P2093
Cameron Ball
Emily Krogstad
Kim A Woodrow
Thanyanan Chaowanachan
P2860
P304
P356
10.1371/JOURNAL.PONE.0061416
P407
P577
2013-01-01T00:00:00Z